BRISTOL-MYERS SQUIBB (BMY) Halts Phase 3 Mavacamten Trial for Lack of Efficacy
The company terminated its Phase 3 study of mavacamten in non-obstructive hypertrophic cardiomyopathy after the drug failed to show short-term efficacy.
Bristol-Myers Squibb (BMY) has terminated a Phase 3 study of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy. The registry entry for the trial, updated on 18 September 2026, lists the status as TERMINATED, with the stated reason that the trial terminated because of lack of efficacy in the short term acute phase.
